RecruitingNCT06561906

Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Enrollment

1,000 participants

Start Date

Sep 1, 2020

Study Type

OBSERVATIONAL

Conditions

Mild Cognitive Impairment Alzheimer Disease, Late Onset Subjective Cognitive Decline

Summary

To establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on combined features of baseline demographic, cognitive, behavioral, multimodal MRI, genetic, and plasma data.

Eligibility

Min Age: 50 YearsMax Age: 79 Years

Plain Language Summary

Simplified for easier understanding

This study aims to build prediction models that can identify people in the very early (pre-clinical) stages of Alzheimer's disease — before any memory or thinking symptoms appear — by combining brain MRI scans, cognitive performance tests, genetic information, and blood-based biomarkers in adults aged 50–79. Early identification could allow for earlier intervention and monitoring. **You may be eligible if...** - You are aged 50–79 - You have completed at least 8 years of formal education **You may NOT be eligible if...** - You have a prior history of stroke, Parkinson's disease, epilepsy, brain tumors, encephalitis, or other neurological conditions that affect cognition - You currently have severe anxiety or depression - You have contraindications to MRI scanning (such as a pacemaker, cochlear implant, or metal implants) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMultimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing

Multimodal magnetic resonance imaging scanning, including 3DT1, 3DT2, 3DFLAIR, functional MRI, DTI, NODDI, ASL, QSM behavioral testing, such as olfaction and spatial navigation genetic testing, such as APOE, BDNF plasma biomarker testing, such as ptau, Aβ42/40、NfL、GFAP